| James Freeman Palmer, DO | |
|
1157 N 300 W, Provo, UT 84604-6124 | |
| (801) 357-7525 | |
| Not Available |
| Full Name | James Freeman Palmer |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 1157 N 300 W, Provo, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417214958 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | 10333270-1204 (Utah) | Primary |
| Entity Name | Walden Behavioral Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992778781 PECOS PAC ID: 0042121659 Enrollment ID: O20041001000593 |
News Archive
Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Biliary Cirrhosis (PBC).
Though it would seem logical, cancer patients don't always choose therapies with the best chance for survival-cost and side effects are also major considerations. Little has been known about the extent to which cost and side effects influence a patient's treatment decision. Now, new findings by Fox Chase Cancer Center researchers reveals that a patient's socioeconomic status, more than any other characteristic-such as age or disease site-is predictive of whether he or she will favor high efficacy, low cost or low toxicity when choosing a treatment.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting.
A team of scientists at the University of Groningen, in the Netherlands, demonstrates that a natural plant product, resveratrol, and its structural analog, pterostilbene, have long-lasting antiviral effects against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the bioRxiv preprint server.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Freeman Palmer, DO 1157 N 300 W, Provo, UT 84604-6124 Ph: (801) 357-7525 | James Freeman Palmer, DO 1157 N 300 W, Provo, UT 84604-6124 Ph: (801) 357-7525 |
News Archive
Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Biliary Cirrhosis (PBC).
Though it would seem logical, cancer patients don't always choose therapies with the best chance for survival-cost and side effects are also major considerations. Little has been known about the extent to which cost and side effects influence a patient's treatment decision. Now, new findings by Fox Chase Cancer Center researchers reveals that a patient's socioeconomic status, more than any other characteristic-such as age or disease site-is predictive of whether he or she will favor high efficacy, low cost or low toxicity when choosing a treatment.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting.
A team of scientists at the University of Groningen, in the Netherlands, demonstrates that a natural plant product, resveratrol, and its structural analog, pterostilbene, have long-lasting antiviral effects against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the bioRxiv preprint server.
› Verified 8 days ago
Edward Leslie Kelly, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 Fax: 801-344-4225 | |
Brent L Griffin, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-4542 | |
Aaron William Sanders, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 395 W Cougar Blvd Ste 601, Provo, UT 84604 Phone: 801-357-7525 | |
Sam J Coates, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-4542 | |
Dr. Rodney A Cheal, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Ms. Madhumathy Gundlapalli, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Dr. Stephen Peters, PSYD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1157 N 300 W, Provo, UT 84604 Phone: 801-357-1200 |